Great Point Partners portfolio
Concentrated managerType not verifiedPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Great Point Partners reported a $424M portfolio of 37 positions to the SEC as of the end of Q2 2026. Its largest positions are VOR, ABVX, VERA. During the quarter it opened Abivax and Definium Therapeutics and exited Apogee Therapeutics and Immunovant.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Great Point Partners has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
- 13GLeonaBioLONA5 %
Stake reported in the company · event of Oct 28, 2026 · filed Nov 4, 2026 · filing ↗
Stake reported in the company · event of Sep 4, 2026 · filed Sep 11, 2026 · filing ↗
- 13GJatt III Acquisition5.8 %
Stake reported in the company · event of Aug 26, 2026 · filed Sep 2, 2026 · filing ↗
- 13G/AScynexisSCYX10 %
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
- 13G/AAmanat AcquisitionAMAN5.2 % → 6.7 %
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
- 13G/APromis NeurosciencesPMN10 % → 7.7 %
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
What changed this quarter
35 positions with a change (8 new, 7 added to, 9 trimmed, 11 sold); also, 2 entered through an IPO, 1 exited through an acquisition or merger. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Newly listedJATT II AcquisitionJATT1.3% of the portfolio
- Newly listedAmanat AcquisitionAMAN1.2% of the portfolio
It started trading this quarter: it appears in a 13F for the first time. The filing does not say whether the manager already held it before the listing, so it is not counted as a purchase.
- Apogee Therapeutics−7.4 ppof portfolioSold out7.7% → —
- Abivax+6.4 ppof portfolioNew— → 6.4%
- Definium Therapeutics+4.7 ppof portfolioNew— → 4.7%
- Amylyx Pharmaceuticals−60%fewer sharesReduced6.0% → 3.0%
- Vera Therapeutics+201%more sharesIncreased2.0% → 6.1%
- Sagimet Biosciences+3.7 ppof portfolioNew— → 3.7%
- Immunovant−3.2 ppof portfolioSold out3.3% → —
- Jade Biosciences−3.2 ppof portfolioSold out3.3% → —
- Zenas BioPharma−2.4 ppof portfolioSold out2.5% → —
- Nektar Therapeutics−45%fewer sharesReduced5.6% → 2.9%
- Immix Biopharma+265%more sharesIncreased0.8% → 3.1%
- Bright Minds Biosciences−50%fewer sharesReduced3.9% → 1.8%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Vor BiopharmaVOR7.4%
- AbivaxABVX6.4%
- Vera TherapeuticsVERA6.1%
- Zura BioZURA5.9%
- AlumisALMS5.7%
- Sol-Gel TechnologiesSLGL4.8%
- Definium TherapeuticsDFTX4.7%
- AnnexonANNX4.7%
- Oruka TherapeuticsORKA4.1%
- Moonlake ImmunotherapeuticsMLTX3.9%
- Sagimet BiosciencesSGMT3.7%
- Contineum TherapeuticsCTNM3.6%
- Immix BiopharmaIMMX3.1%
- Climb BioCLYM3.1%
- Amylyx PharmaceuticalsAMLX3.0%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 97%
- ● SPAC / vehículos 3%
How its portfolio changed (8 quarters)
Q2 2026: 37
Q2 2026: 54%
Q2 2026: 35.3%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Declared options (5)
Besides stocks, Great Point Partners declared 2 puts (they gain if the stock falls) and 3 calls (they gain if it rises) with a notional of $105M. The 13F reports the value of the underlying shares, not the premium paid, so these figures look large and are not added to the portfolio. Nor does it say whether the option is bought or written, or its strike or expiry: it may be a hedge.
- CALLAbivaxABVXnew this quarter$53.3M
- PUTImmunitybioIBRX$26.3M
- PUTUltragenyx PharmaceuticalRAREnew this quarter$20.0M
- CALLGalectin TherapeuticsGALT$3.7M
- CALLAnavex Life SciencesAVXL$1.4M
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Type not verified. It meets the portfolio criteria of a concentrated manager, but its type is not verified: we found no official document that is enough to say what kind of entity it is. It may be an investment firm, but also an adviser adding up client accounts, a bank or a family vehicle. It counts in the tallies like the rest; keep that in mind when reading it. How the type is assigned
Managers of a similar size
A 13F portfolio value between a third and three times this one, whatever the type of filer. It is not a comparison of what they hold.
- Miller Value PartnersInvestment firm · $423M
- Birinyi Associates$423M
- Westwind Capital$426M
- Oldfield Partners LLPInvestment firm · $428M
- CAT Rock Capital ManagementInvestment firm · $431M
- Grandeur Peak Global AdvisorsInvestment firm · $432M